What is Venus?
Venus specializes in the development and distribution of clinically validated medical aesthetic equipment, providing a comprehensive suite of solutions that includes body contouring, radio frequency therapies, and advanced laser hair removal systems. By focusing on user-friendly interfaces and proven clinical outcomes, the company has established a strong reputation among medical practitioners in the United States and Canada. Beyond hardware, Venus distinguishes itself through a value-added service model that encompasses technical support, business growth initiatives, and rigorous onboarding processes. This holistic approach ensures that clinics can maximize operational efficiency while delivering superior patient satisfaction, effectively bridging the gap between high-end medical technology and practical clinical application.
How much funding has Venus raised?
Venus has raised a total of $143.8M across 9 funding rounds:
Private Equity
$10M
Debt
$20M
Private Equity
$38M
Multiple Rounds
$55.3M
Share Placement
$17M
Debt
$2M
Private Equity
$1.5M
Private Equity (2014): $10M with participation from Longitude Capital
Debt (2015): $20M led by Oxford Finance
Private Equity (2017): $38M supported by HealthQuest Capital and Essex Woodlands
Share Placement (2020): $22.3M featuring SEDCO Capital, HealthQuest Capital, and Essex Woodlands
Debt (2020): $2M backed by PPP
Share Placement (2020): $31M with participation from Lincoln Park Capital Fund , LLC
Share Placement (2021): $17M led by Masters Special Situations, HealthQuest Capital, and Essex Woodlands
Debt (2025): $2M supported by Madryn Asset Management
Private Equity (2026): $1.5M, investors not publicly disclosed
Key Investors in Venus
Essex Woodlands
EW Healthcare Partners is one of the largest and oldest private healthcare investment firms, specializing in growth equity for commercial-stage companies in the medical device and diagnostics sectors.
HealthQuest Capital
HealthQuest Capital focuses on providing growth capital to innovative healthcare companies that are transforming the industry through improved patient outcomes and operational efficiency.
Longitude Capital
Longitude Capital is a healthcare-focused venture capital firm that invests in biotechnology and medical technology, pairing sector expertise with flexible capital to help innovators scale.
What's next for Venus?
With the recent $1.5M capital injection, Venus is well-positioned to accelerate its research and development pipeline, focusing on the next generation of aesthetic technologies. The company's strategic roadmap likely involves deepening its penetration into the North American market while potentially exploring new therapeutic applications for its existing radio frequency and laser platforms. By maintaining its focus on high-growth commercial-stage healthcare, Venus aims to leverage its recent financing to enhance its competitive moat, ensuring that its technological innovations continue to drive long-term value for both clinical partners and stakeholders. The firm remains dedicated to its core mission of providing safe, effective, and reliable aesthetic solutions in an increasingly competitive landscape.
See full Venus company page
